骨髓增生异常综合征患者血清白介素-35表达水平及其诱导产生的新型调节性T细胞iTR35比例和临床意义
发布时间：2018-07-17 01:21
【摘要】：目的:探讨骨髓增生异常综合征(MDS)患者血清新型免疫抑制因子——IL-35表达水平及其诱导产生的新型调节性T细胞iTR35的临床意义。方法:选取2014年1月至2016年1月福建省泉州市第一医院血液科收治的23例初诊MDS患者为研究对象,根据MDS国际预后积分系统(IPSS)将其分为高危(n=4),中危-2(n=10),中危-1(n=5)和低危型(n=4)4个亚组。选取同期在我院体检的20例正常人为正常对照组。分别采用酶联免疫吸附试验(ELISA)和流式细胞术(FCM)检测各亚组患者血清IL-35表达水平及iTR35细胞比例。结果:MDS组患者外周血CD4~+CD25~+Foxp3~+Treg细胞比例显著高于对照组(P0.01),iTR35细胞比例高于正常对照(P0.01),而两组的CD4~+CD25~-Foxp3~+Treg细胞比例无显著的统计学差异(P0.05)。MDS组的血清IL-35水平显著高于对照组(P0.05),Treg细胞内IL-12p35和IL-27EBl3表达水平也较对照组显著上调(P0.05),且MDS组的血清IL-35水平与IL-12p35和IL-27EBl3表达水平及iTR35细胞比例呈正相关(r分别为0.92、0.99和0.52,P0.05)。MDS的4个亚组中,iTR35细胞比例及血清IL-35表达水平总体具有显著性差异(P0.05),高危组与中危-2组患者的血清IL-35水平无明显差别(P0.05),但两组均分别明显高于中危-1组和低危组(P0.05),中危-2组也明显高于中危-1组及低危组(P0.05),而中危-1组与低危组无差别(P0.05)。高危组与中危-2组的iTR35细胞比例无显著差别,但高危组和中危-2组的iTR35细胞比例均显著高于中危1组和低危组(P0.05),而中危1组与低危组无明显差别(P0.05)。结论:IL-35水平和iTR35细胞的数量和(或)功能失衡在MDS发生、发展过程中起着重要作用,有望为MDS免疫靶向治疗研究提供新的理论依据。
[Abstract]:Aim: to investigate the expression level of serum novel immunosuppressive factor-IL-35 in patients with myelodysplastic syndrome (MDS) and its clinical significance in inducing new regulatory T cell iTR35. Methods: from January 2014 to January 2016, 23 newly diagnosed MDS patients in Department of Hematology, first Hospital of Quanzhou City, Fujian Province were selected as study subjects. According to the International prognosis integral system (IPSS) of MDS, they were divided into 4 subgroups: high risk (nong4), moderate risk 2 (nong10), moderate risk 1 (nong5) and low risk type (n4). 20 normal subjects in our hospital were selected as the normal control group. Elisa and FCM were used to detect the expression of IL-35 in serum and the proportion of iTR35 cells in each subgroup. Results the percentage of CD4 ~ CD25 ~ Foxp3 ~ Treg cells in the patients with MDS was significantly higher than that in the control group (P0.01). However, there was no significant difference in the proportion of CD4 ~ CD25- Foxp3 ~ Treg cells between the two groups (P0.05). The level of serum IL-35 in the MDS group was significantly higher than that in the control group (P0.01). The expression of IL-12p35 and IL-27EBl3 in Treg cells in the MDS group was significantly higher than that in the control group (P0.05), and the serum IL-35 level was positively correlated with the expression of IL-12p35 and IL-27EBl3 and the proportion of iTR35 cells in the MDS group (r = 0.92, 0.99 and 0.52P0.05, respectively). The percentage of iTR35 cells and the percentage of serum iTR35 cells in MDS subgroups were positively correlated with the expression levels of IL-12p35 and IL-27EBl3 in MDS group (r = 0.92, 0.99 and 0.52P0.05, respectively). The level of IL-35 expression was significantly higher in the high risk group than in the middle risk group (P0.05), but the level of IL-35 in the high risk group was significantly higher than that in the moderate risk group and the low risk group (P0.05), and the level of IL-35 in the middle risk group was significantly higher than that in the middle risk group and the middle risk group (P0.05). Low risk group (P0.05), but moderate risk-1 group and low risk group had no difference (P0.05). There was no significant difference in the proportion of iTR35 cells between high risk group and moderate risk 2 group, but the proportion of iTR35 cells in high risk group and middle risk 2 group was significantly higher than that in middle risk 1 group and low risk group (P0.05), but there was no significant difference between middle risk group and low risk group (P0.05). Conclusion the imbalance of cell number and / or function in MDS may play an important role in the pathogenesis and development of MDS, which is expected to provide a new theoretical basis for the study of MDS immunoreactive therapy.
【作者单位】： 福建医科大学附属泉州第一医院血液科;
【分类号】：R551.3
，
本文编号：2128402
[Abstract]:Aim: to investigate the expression level of serum novel immunosuppressive factor-IL-35 in patients with myelodysplastic syndrome (MDS) and its clinical significance in inducing new regulatory T cell iTR35. Methods: from January 2014 to January 2016, 23 newly diagnosed MDS patients in Department of Hematology, first Hospital of Quanzhou City, Fujian Province were selected as study subjects. According to the International prognosis integral system (IPSS) of MDS, they were divided into 4 subgroups: high risk (nong4), moderate risk 2 (nong10), moderate risk 1 (nong5) and low risk type (n4). 20 normal subjects in our hospital were selected as the normal control group. Elisa and FCM were used to detect the expression of IL-35 in serum and the proportion of iTR35 cells in each subgroup. Results the percentage of CD4 ~ CD25 ~ Foxp3 ~ Treg cells in the patients with MDS was significantly higher than that in the control group (P0.01). However, there was no significant difference in the proportion of CD4 ~ CD25- Foxp3 ~ Treg cells between the two groups (P0.05). The level of serum IL-35 in the MDS group was significantly higher than that in the control group (P0.01). The expression of IL-12p35 and IL-27EBl3 in Treg cells in the MDS group was significantly higher than that in the control group (P0.05), and the serum IL-35 level was positively correlated with the expression of IL-12p35 and IL-27EBl3 and the proportion of iTR35 cells in the MDS group (r = 0.92, 0.99 and 0.52P0.05, respectively). The percentage of iTR35 cells and the percentage of serum iTR35 cells in MDS subgroups were positively correlated with the expression levels of IL-12p35 and IL-27EBl3 in MDS group (r = 0.92, 0.99 and 0.52P0.05, respectively). The level of IL-35 expression was significantly higher in the high risk group than in the middle risk group (P0.05), but the level of IL-35 in the high risk group was significantly higher than that in the moderate risk group and the low risk group (P0.05), and the level of IL-35 in the middle risk group was significantly higher than that in the middle risk group and the middle risk group (P0.05). Low risk group (P0.05), but moderate risk-1 group and low risk group had no difference (P0.05). There was no significant difference in the proportion of iTR35 cells between high risk group and moderate risk 2 group, but the proportion of iTR35 cells in high risk group and middle risk 2 group was significantly higher than that in middle risk 1 group and low risk group (P0.05), but there was no significant difference between middle risk group and low risk group (P0.05). Conclusion the imbalance of cell number and / or function in MDS may play an important role in the pathogenesis and development of MDS, which is expected to provide a new theoretical basis for the study of MDS immunoreactive therapy.
【作者单位】： 福建医科大学附属泉州第一医院血液科;
【分类号】：R551.3
，
本文编号：2128402
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2128402.html
最近更新
教材专著
